The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Using peripheral blood ctDNA-sequencing for PCNSL risk profiling
Sven Borchmann, MD, University of Cologne, Cologne, Germany, discusses a novel strategy to carry out risk profiling in primary central nervous system lymphoma (PCNSL). Biopsies may not be feasible in a number of patients and measuring circulating tumor DNA (ctDNA)-based peripheral residual disease (PRD) has shown to be a promising tool to guide treatment in patients with PCNSL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Liqomics: Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees; Galapagos: Consultancy.
